Hrishi Kale

Hrishi Kale

Hrishikesh P. Kale

Service Area
Real-World Evidence & Data Analytics; Patient-Reported Outcomes
Role
Associate Scientist
Degree(s)
PhD
Office
Bethesda, United States

Hrishikesh P. Kale, PhD, is an Associate Scientist in Real-World Evidence and Patient-Reported Outcomes, located in Pharmerit’s Bethesda office. He has experience with studies pertaining to comparative effectiveness and safety, burden of illness, treatment patterns, medication adherence and quality of life. He is well versed with analysis of data from SEER-Medicare, MarketScan, National Poison Data System, Adverse Event Reporting System and MEPS. He also brings experience with systematic literature reviews and economic modeling. His projects have covered many therapeutic areas including the following: oncology, pain, opioid abuse, multiple sclerosis, respiratory, rheumatology, hepatitis-C, biosimilars, rare disease, and depression.

Prior to joining Pharmerit, Hrishikesh earned PhD in Pharmacoeconomics and Health Outcomes from Virginia Commonwealth University (VCU). At VCU, he conducted research around cancer survivorship, adherence to specialty therapies, economic burden of renal cell carcinoma, and cost-effectiveness of hepatitis-C therapies. One of his publication on the financial burden of cancer care received a widespread national media coverage. He was the recipient of a dissertation fellowship and the Victor A. Yanchick Dean’s award, given for excellence in research and scholarship.

Additionally, he worked for 3 years within Purdue Pharma L.P., in Stamford, CT across a breadth of roles including statistical analysis, SAS programming, scientific writing, and project management. His research around abuse-deterrent formulations and pain management resulted in several FDA required post-marketing epidemiology reports, risk management plans, presentations to conferences and regulatory agencies, and peer-reviewed manuscripts.

Hrishikesh is also involved in voluntary and leadership activities with International Society for Pharmacoeconomics and Outcomes Research (ISPOR), ISPOR Oncology Modeling Special Interest Group and Academy of Managed Care Pharmacy.

2018-10-02T15:09:57+00:00 September 13th, 2018|